Incidentally recognised thyroid focal uptake of XXXX during stress myocardial perfusion scintigraphy.

@entity1 @entity3557 @entity4424 @entity296 @entity1669 @entity787 @entity10979 @entity1374
INTRODUCTION: @entity10979 , a radiopharmaceutical widely used in the assessment of myocardial perfusion, can be used as an indicator of @entity1374 due to its oncophilic character. The aim of this study was to establish the usefulness of performing additional examinations of radiotracer uptake in the thyroid gland during standard stress scintigraphy with sestamibi in order to identify @entity1374 . MATERIAL AND METHODS: After a retrospective evaluation of 330 consecutive myocardial perfusion scintigraphies performed in our hospital during one year, 41 @entity1 with a focal accumulation of @entity10979 in the thyroid were enrolled in the study. The @entity1 underwent clinical examinations, including thyroid ultrasonography and TSH, fT4, fT3, @entity4424 , TRAB, calcitonin, and @entity787 levels. Based on the thyroid ultrasounds, 21 @entity1 were referred for fine-needle aspiration biopsy of the thyroid. RESULTS: An abnormal accumulation of radiotracer in the thyroid was found in 41(12.4%) of 330 @entity1 who underwent stress cardiac scintigraphy. Thirteen (31.7%) of those @entity1 had multinodular euthyroid goitres, 12 (29.2%) had a single thyroid nodule (including two autonomous nodules), 11 (26.8%) had @entity1669 , and one (2.4%) had @entity3557 . In 12 (29.2%) with thyroid tracer uptake there was no thyroid pathology. CONCLUSIONS: Additional evaluation of radiotracer uptake in the thyroid during standard myocardial perfusion scintigraphy is a valuable tool in the detection of @entity1374 . The additional or parallel evaluation of radiotracer uptake in the thyroid should be considered during every @entity296 . (Endokrynol Pol 2015; 66 (6): 521-525).
